Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 49-55

  Burmester, Gerd R ^a   Durez, Patrick ^b   Shestakova, Galina ^c   Genovese, Mark C ^d   Schulze Koops, Hendrik ^e   Li, Yue ^f   Wang, Ying A ^g   Lewitzky, Steve ^g   Koroleva, Irina ^g   Berneis, Anni Agarwal ^f   Lee, David M ^f   Hueber, Wolfgang ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c City Clinical Hospital No39   (Russian Federation)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

biomarker; C reactive protein; clinical trial; genetic; HLA; interleukin 17; Rheumatoid arthritis; rheumatoid factor; secukinumab

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; EPITOPE; HLA DRB1 ANTIGEN; INTERLEUKIN 17; PLACEBO; SECUKINUMAB;

ACR20 SCORE; ALLELE; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTADENOMA; DAS28; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; HUMAN; INSOMNIA; JOINT DISLOCATION; JOINT SWELLING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NAUSEA; NECROTIZING ARTERITIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84959135589     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev258     Document Type: Article

References (21)

1. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
2. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology 2014;53:1560-9.
3. Burmester GR, Feist E, Dörner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:77-88.
4. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
5. Genovese MC, Greenwald MW, Cho CS et al. A phase 2 study of multiple subcutaneous doses of LY2439821 (ixekizumab), an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. Abstract presented at: 2012 Annual Meeting of the European League Against Rheumatism (EULAR); Berlin, Germany; 6-9 June 2012. Abstract OP0021.
6. Genovese MC, Durez P, Richards HB et al. Efficacy and safety of secukinumab in subjects with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo-controlled study. Ann Rheum Dis 2013;72:863-9.
7. Genovese MC, Durez P, Richards HB et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014;41:414-21.
8. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002;31:355-60.
9. Fries JF, Wolfe F, Apple R et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002;46:2320-9.
10. van der Helm-van Mil AH, Verpoort KN, Breedveld FC et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117-21.
11. Feitsma AL, van der Voort EI, Franken KL et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010;62:117-25.
12. Raychaudhuri S, Sandor C, Stahl EA et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012;44:291-6.
13. de Almeida DE, Ling S, Holoshitz J. New insights into the functional role of the rheumatoid arthritis shared epitope. FEBS Lett 2011;585:3619-26.
14. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
15. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
16. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
17. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in subjects with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73:349-56.
18. Baeten D, Baraliakos X, Braun J et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebocontrolled trial. Lancet 2013;382:1705-13.
19. Sanmartí R, Gómez-Centeno A, Ercilla G et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007;26:1111-8.
20. Goronzy JJ, Matteson EL, Fulbright JW et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43-54.
21. Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011;70:2063-70.